콘텐츠로 건너뛰기
Merck
모든 사진(1)

주요 문서

926345

Sigma-Aldrich

NanoFabTx-DC-Chol Lipid Mix

for synthesis of cationic (DC-cholesterol) liposomes

로그인조직 및 계약 가격 보기


About This Item

UNSPSC 코드:
12162002
NACRES:
NA.23

Quality Level

저장 온도

−20°C

일반 설명

NanoFabTx-DC-Chol Lipid Mix; for synthesis of cationic (DC-cholesterol) liposomes is a ready-to-use nanoformulation blend for the synthesis of liposomes for drug delivery. The NanoFabTx-DC-Chol Lipid Mix includes optimized protocols with step-by-step instructions for synthesizing cationic DC-cholesterol liposomes for drug delivery applications. The modification of the liposomes with the cationic lipid, DC-cholesterol, have numerous advantages including high gene transfection efficiency. Liposome-based formulations are widely used for drug delivery applications and enable improved therapeutic efficacy of a range of drug types including small molecules, nucleic acids, proteins, and peptides.

애플리케이션

About NanoFabTx

NanoFabTx lipid mixes and formulation kits enable users to encapsulate a wide variety of therapuetic drug molecules for targeted or extended drug delivery without the need for lengthy trial-and-error optimization. NanoFabTx reagent kits provide an easy-to-use toolkit for encapsulating a variety of therapeutics in nanoparticles, microparticles, or liposomes. Drug encapsulated particles synthesized with the NanoFabTx kits are suitable for biomedical research applications such as oncology, immuno-oncology, gene delivery, and vaccine delivery.

특징 및 장점

  • A ready-to-use nanoformulation blend for the synthesis of cationic DC-cholesterol liposomes
  • Step-by-step protocols (extrusion or microfluidic) developed and tested by our formulation scientists
  • Flexible synthesis tools to create uniform and reproducible liposomes
  • Optimized to make liposomes around 100 nm with low polydispersity
  • DC-Cholesterol allows for high transfection efficiency and targeted drug delivery
Comprehensive protocols for liposome synthesis are included:
  • A lipid film hydration and extrusion protocol.
  • A microfluidics protocol using commercial platforms or syringe pumps.
The microfluidics protocol included with this product uses the NanoFabTx device kit (911593). These kits are ready-to-use and include the microfluidic chip, fittings, and tubing required for microfluidics-based synthesis (compatible microfluidics system or syringe pump required).

법적 정보

NANOFABTX is a trademark of Sigma-Aldrich Co. LLC

Storage Class Code

11 - Combustible Solids

WGK

WGK 3


가장 최신 버전 중 하나를 선택하세요:

시험 성적서(COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 문서 section.

도움이 필요하시면 연락하세요. 고객 지원 부서

이 제품을 이미 가지고 계십니까?

문서 라이브러리에서 최근에 구매한 제품에 대한 문서를 찾아보세요.

문서 라이브러리 방문

Characterization of liposomal systems containing doxorubicin entrapped in response to pH gradients.
Mayer LD, et al.
Biochimica et Biophysica Acta, 1025, 143-151 (1990)
Recent advances on liposomal nanoparticles: synthesis, characterization and biomedical applications
Panahi Y, et al.
Artificial Cells, Nanomedicine, and Biotechnology (Print), 45, 788-799 (2017)
Which polymers can make nanoparticulate drug carriers long-circulating?
Torchilin VP, et al.
Advanced Drug Delivery Reviews, 16, 141?155-141?155 (1995)
Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy
Papahadjopoulos D, et al.
Proceedings of the National Academy of Sciences of the USA, 88, 11460-11464 (1991)
T D Madden et al.
Chemistry and physics of lipids, 53(1), 37-46 (1990-03-01)
We have shown previously that transmembrane proton gradients can be used to efficiently accumulate biogenic amines [M.B. Bally et al. (1988) Chem. Phys. Lipids 47, 97-107] and doxorubicin [L.D. Mayer, M.B. Bally and P.R. Cullis (1986) Biochim. Biophys. Acta 857

자사의 과학자팀은 생명 과학, 재료 과학, 화학 합성, 크로마토그래피, 분석 및 기타 많은 영역을 포함한 모든 과학 분야에 경험이 있습니다..

고객지원팀으로 연락바랍니다.